Literature DB >> 23745552

Subthreshold laser therapy for diabetic macular edema: metabolic and safety issues.

Stela Vujosevic1, Ferdinando Martini, Enrica Convento, Evelyn Longhin, Olympia Kotsafti, Raffaele Parrozzani, Edoardo Midena.   

Abstract

PURPOSE: To review the most important metabolic effects and clinical safety data of subthreshold micropulse diode laser (D-MPL) in diabetic macular edema (DME).
METHODS: Review of the literature about the mechanisms of action and role of D-MPL in DME.
RESULTS: The MPL treatment does not damage the retina and is selectively absorbed by the retinal pigment epithelium (RPE). MPL stimulates secretion of different protective cytokines by the RPE. No visible laser spots on the retina were noted on any fundus image modality in different studies, and there were no changes of the outer retina integrity. Mean central retinal sensitivity (RS) increased in subthreshold micropulse diode laser group compared to standard ETDRS photocoagulation group.
CONCLUSIONS: MPL is a new, promising treatment option in DME, with both infrared and yellow wavelengths using the less aggressive duty cycle (5%) and fixed power parameters. It appears to be safe from morphologic and functional point of view in mild center involving DME.

Entities:  

Mesh:

Year:  2013        PMID: 23745552     DOI: 10.2174/09298673113209990030

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  19 in total

1.  Comparative efficacy of pure yellow (577-nm) and 810-nm subthreshold micropulse laser photocoagulation combined with yellow (561-577-nm) direct photocoagulation for diabetic macular edema.

Authors:  Keiji Inagaki; Kishiko Ohkoshi; Sachiko Ohde; Gautam A Deshpande; Nobuyuki Ebihara; Akira Murakami
Journal:  Jpn J Ophthalmol       Date:  2014-11-14       Impact factor: 2.447

Review 2.  A review of therapies for diabetic macular oedema and rationale for combination therapy.

Authors:  W M K Amoaku; S Saker; E A Stewart
Journal:  Eye (Lond)       Date:  2015-06-26       Impact factor: 3.775

3.  Comparison of the efficacy and safety of anti-VEGF monotherapy versus anti-VEGF therapy combined with subthreshold micropulse laser therapy for diabetic macular edema.

Authors:  Meltem Guzin Altınel; Banu Acikalin; Meryem Guler Alis; Gokhan Demir; Kemal Mert Mutibayraktaroglu; Ozgun Melike Gedar Totuk; Aylin Ardagil
Journal:  Lasers Med Sci       Date:  2021-04-04       Impact factor: 3.161

4.  Increase in Central Retinal Edema after Subthreshold Diode Micropulse Laser Treatment of Chronic Central Serous Chorioretinopathy.

Authors:  Maciej Gawęcki
Journal:  Case Rep Ophthalmol Med       Date:  2015-06-09

Review 5.  A Review on Recent Developments for Detection of Diabetic Retinopathy.

Authors:  Javeria Amin; Muhammad Sharif; Mussarat Yasmin
Journal:  Scientifica (Cairo)       Date:  2016-09-29

6.  Functional and morphological outcome in patients with chronic central serous chorioretinopathy treated by subthreshold micropulse laser.

Authors:  Maciej Gawęcki; Agnieszka Jaszczuk-Maciejewska; Anna Jurska-Jaśko; Andrzej Grzybowski
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-08-22       Impact factor: 3.117

Review 7.  Diabetic Retinopathy: Pathophysiology and Treatments.

Authors:  Wei Wang; Amy C Y Lo
Journal:  Int J Mol Sci       Date:  2018-06-20       Impact factor: 5.923

Review 8.  Aqueous humour concentrations of PEDF and Erythropoietin are not influenced by subthreshold micropulse laser treatment of diabetic macular edema.

Authors:  Edoardo Midena; Silvia Bini; Luisa Frizziero; Elisabetta Pilotto; Graziana Esposito; Alessandra Micera
Journal:  Biosci Rep       Date:  2019-06-18       Impact factor: 3.840

9.  Minimally invasive laser treatment combined with intravitreal injection of anti-vascular endothelial growth factor for diabetic macular oedema.

Authors:  Keiji Inagaki; Masafumi Hamada; Kishiko Ohkoshi
Journal:  Sci Rep       Date:  2019-05-20       Impact factor: 4.379

10.  Microsecond yellow laser for subfoveal leaks in central serous chorioretinopathy.

Authors:  Vikas Ambiya; Abhilash Goud; Annie Mathai; Padmaja Kumari Rani; Jay Chhablani
Journal:  Clin Ophthalmol       Date:  2016-08-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.